Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ge Yu
Observed name:
Yu, Ge
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
Junshi Biosciences (China),
Tianjin Medical University
Observed institutions:
Florida State University,
Houston Methodist,
Jilin University,
Tianjin Medical University Cancer Institute and Hospital,
First Hospital of Jilin University,
First Bethune Hospital of Jilin University,
Junshi Biosciences (China),
Tianjin Medical University
show all 8
ORCID:
0000-0003-0101-9478
Observed ORCID:
0000-0003-0101-9478
OpenAlex ID:
A5101552247
Predictive value of elevated alanine aminotransferase for in-hospital mortality in patients with acute myocardial infarction
2021
·
Jian Li
, Zhuo Zhao
, et al.
·
BMC Cardiovascular Disorders
·
45
PDF
Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population
2015
·
Ge Yu
, Xiumei Chi
, et al.
·
PLoS ONE
·
38
PDF
Gallstones in Patients with Chronic Liver Diseases
2017
·
Xu Li
, Xiaolin Guo
, et al.
·
BioMed Research International
·
37
PDF
Pih1p-Tah1p Puts a Lid on Hexameric AAA+ ATPases Rvb1/2p
2017
·
Shaoxiong Tian
, Ge Yu
, et al.
·
Structure
·
31
Association of Hepatitis C and B Virus Infection with CKD and Impact of Hepatitis C Treatment on CKD
2019
·
Hui Zhang
, Hongqin Xu
, et al.
·
Scientific Reports
·
30
PDF
Factors Associated with Spontaneous Clearance of Hepatitis C Virus in Chinese Population
2014
·
Fei Kong
, Yu Pan
, et al.
·
BioMed Research International
·
30
PDF
IFN-λ4 desensitizes the response to IFN-α treatment in chronic hepatitis C through long-term induction of USP18
2016
·
Weiguo Fan
, Shiqi Xie
, et al.
·
Journal of General Virology
·
22
Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy
2017
·
Huan Li
, Shuanghui Yang
, et al.
·
Theranostics
·
19
PDF
High prevalence of Clonorchis sinensis infections and coinfection with hepatitis virus in riverside villages in northeast China
2020
·
Yanhang Gao
, Yanqing Li
, et al.
·
Scientific Reports
·
18
PDF
Co-Expression and Co-Purification of Archaeal and Eukaryal Box C/D RNPs
2014
·
Yu Peng
, Ge Yu
, et al.
·
PLoS ONE
·
18
PDF
The association of hepatitis c virus infection status with serum glucose levels
2019
·
Yinping Li
, Xiaomei Wang
, et al.
·
BMC Gastroenterology
·
15
PDF
ssDNA Aptamer Specifically Targets and Selectively Delivers Cytotoxic Drug Doxorubicin to HepG2 Cells
2016
·
Ge Yu
, Huan Li
, et al.
·
PLoS ONE
·
15
PDF
Use of parenteral caffeinum natrio-benzoicum: an underestimated risk factor for HCV transmission in China
2015
·
Hongqin Xu
, Ge Yu
, et al.
·
BMC Public Health
·
14
PDF
Yeast R2TP Interacts with Extended Termini of Client Protein Nop58p
2019
·
Ge Yu
, Yu Zhao
, et al.
·
Scientific Reports
·
9
PDF
IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection
2016
·
Ruihong Wu
, Xiumei Chi
, et al.
·
Infection Genetics and Evolution
·
7
PDF
Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025
·
Ningning Zhang
, Tian Liu
, et al.
·
Clinical Cancer Research
·
4
Case report of acute liver injury caused by the eszopiclone in a patient with chronic liver disease
2021
·
Tong Wu
, Ge Yu
, et al.
·
Medicine
·
4
Sustained viral response and treatment‐induced cytopenia correlate with SLC s and KLF12 genotypes in interferon/ribavirin‐treated Chinese chronic hepatitis C patients
2016
·
Ruqi Mei
, Xiumei Chi
, et al.
·
Journal of Gastroenterology and Hepatology
·
4
PDF
Pharmacokinetics and Safety of VV116 in Subjects With Mild or Moderate Hepatic Impairment Compared With Healthy Controls: A Phase I, Open‐Label Study
2026
·
Xi Tan
, Tong Lu
, et al.
·
Clinical Pharmacology in Drug Development
·
1
Pharmacokinetics and Safety of Deuremidevir Hydrobromide (JT001) in Subjects with Mild and Moderate Renal Impairment: An Open‐Label, Parallel‐Group Phase I Study
2026
·
Tong Lu
, Xi Tan
, et al.
·
The Journal of Clinical Pharmacology
Safety and efficacy of hepatic artery infusion chemotherapy (HAIC) or lenvatinib combined with sintilimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma: A prospective, randomized, two-cohort, exploratory phase II clinical study.
2026
·
Yunlong Cui
, Chen Liu
, et al.
·
Journal of Clinical Oncology
PDF
Data from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025
·
Ningning Zhang
, Tian Liu
, et al.
Supplementary Figure S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025
·
Ningning Zhang
, Tian Liu
, et al.
Supplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025
·
Ningning Zhang
, Tian Liu
, et al.
Supplementary Figure S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025
·
Ningning Zhang
, Tian Liu
, et al.
Show more works
View as search
Works count:
32
Citation count:
361
H-index:
13
I10-index:
13
Year
Topic
Type